Free Trial

ArriVent BioPharma (AVBP) Stock Price, News & Analysis

$19.63
+1.24 (+6.74%)
(As of 07/15/2024 ET)
Today's Range
$18.07
$19.64
50-Day Range
$16.60
$20.15
52-Week Range
$14.35
$25.95
Volume
62,515 shs
Average Volume
71,897 shs
Market Capitalization
$657.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.25

ArriVent BioPharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
49.0% Upside
$29.25 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.88mentions of ArriVent BioPharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.07) to ($3.13) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.96 out of 5 stars

Medical Sector

821st out of 913 stocks

Pharmaceutical Preparations Industry

384th out of 432 stocks

AVBP stock logo

About ArriVent BioPharma Stock (NASDAQ:AVBP)

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

AVBP Stock Price History

AVBP Stock News Headlines

I spent 44 years on Wall Street. If you knew what I know, you’d be terrified too.
Wall Street Legend on Economy: "If you knew what I know, you'd be terrified too." Something huge is headed to America's shores – and it scares the hell out of Wall St. legend Louis Navellier. When it makes landfall, its impact will be more violent and more severe than any financial crisis we've ever seen… "No matter how prepared you think you are, you aren't prepared enough," he warns.
I spent 44 years on Wall Street. If you knew what I know, you’d be terrified too.
Wall Street Legend on Economy: "If you knew what I know, you'd be terrified too." Something huge is headed to America's shores – and it scares the hell out of Wall St. legend Louis Navellier. When it makes landfall, its impact will be more violent and more severe than any financial crisis we've ever seen… "No matter how prepared you think you are, you aren't prepared enough," he warns.
ArriVent BioPharma reports FY results
Arrivent Biopharma Inc (AVBP)
See More Headlines
Receive AVBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/08/2024
Today
7/16/2024
Next Earnings (Estimated)
8/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AVBP
Previous Symbol
NASDAQ:AVBP
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$29.25
High Stock Price Target
$35.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+49.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($4.79) per share

Miscellaneous

Free Float
N/A
Market Cap
$657.41 million
Optionable
N/A
Beta
N/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Zhengbin Yao Ph.D. (Age 58)
    Co-Founder, Chairman, President & CEO
    Comp: $791.09k
  • Dr. Stuart Lutzker M.D. (Age 63)
    Ph.D., Co-Founder, President of Research & Development and Director
    Comp: $709.43k
  • Ms. Robin LaChapelle M.A. (Age 51)
    Co-Founder & COO
    Comp: $586.45k
  • Mr. Winston Kung M.B.A. (Age 48)
    CFO & Treasurer
  • Ms. Yang Wang Ph.D.
    Chief Technology Officer
  • Mr. James Paul Kastenmayer J.D. (Age 52)
    Ph.D., General Counsel & Secretary
  • Dr. Dandan Dong (Age 39)
    Chief Business Officer
  • Ms. Meghna Chowdary
    Senior Vice President of Commercial Strategy

AVBP Stock Analysis - Frequently Asked Questions

How have AVBP shares performed this year?

ArriVent BioPharma's stock was trading at $20.00 at the beginning of the year. Since then, AVBP shares have decreased by 1.9% and is now trading at $19.63.
View the best growth stocks for 2024 here
.

How were ArriVent BioPharma's earnings last quarter?

ArriVent BioPharma, Inc. (NASDAQ:AVBP) posted its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.14.

When did ArriVent BioPharma IPO?

ArriVent BioPharma (AVBP) raised $175 million in an IPO on Friday, January 26th 2024. The company issued 9,722,222 shares at a price of $18.00 per share.

When does the company's lock-up period expire?

ArriVent BioPharma's lock-up period expires on Wednesday, July 24th. ArriVent BioPharma had issued 9,722,222 shares in its IPO on January 26th. The total size of the offering was $174,999,996 based on an initial share price of $18.00. After the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

How do I buy shares of ArriVent BioPharma?

Shares of AVBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVBP) was last updated on 7/16/2024 by MarketBeat.com Staff

From Our Partners